Market closed
AnaptysBio/$ANAB
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About AnaptysBio
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Ticker
$ANAB
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
117
Website
AnaptysBio Metrics
BasicAdvanced
$618M
Market cap
-
P/E ratio
-$6.04
EPS
-0.24
Beta
-
Dividend rate
Price and volume
Market cap
$618M
Beta
-0.24
52-week high
$41.31
52-week low
$13.36
Average daily volume
522K
Financial strength
Current ratio
10.225
Quick ratio
10.08
Long term debt to equity
432.836
Total debt to equity
435.073
Interest coverage (TTM)
-3.72%
Management effectiveness
Return on assets (TTM)
-17.85%
Return on equity (TTM)
-161.81%
Valuation
Price to revenue (TTM)
9.738
Price to book
7.33
Price to tangible book (TTM)
7.33
Price to free cash flow (TTM)
-5.385
Growth
Revenue change (TTM)
282.17%
Earnings per share change (TTM)
11.88%
3-year revenue growth (CAGR)
-22.36%
3-year earnings per share growth (CAGR)
170.22%
What the Analysts think about AnaptysBio
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for AnaptysBio stock.
AnaptysBio Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
AnaptysBio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
AnaptysBio News
AllArticlesVideos
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
GlobeNewsWire·2 weeks ago
Anaptys Announces Participation in November and December Investor Conferences
GlobeNewsWire·2 weeks ago
Anaptys Announces Participation in September Investor Conferences
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for AnaptysBio stock?
AnaptysBio (ANAB) has a market cap of $618M as of November 22, 2024.
What is the P/E ratio for AnaptysBio stock?
The price to earnings (P/E) ratio for AnaptysBio (ANAB) stock is 0 as of November 22, 2024.
Does AnaptysBio stock pay dividends?
No, AnaptysBio (ANAB) stock does not pay dividends to its shareholders as of November 22, 2024.
When is the next AnaptysBio dividend payment date?
AnaptysBio (ANAB) stock does not pay dividends to its shareholders.
What is the beta indicator for AnaptysBio?
AnaptysBio (ANAB) has a beta rating of -0.24. This means that it has an inverse relation to market volatility.